BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 12582448)

  • 1. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
    Hernández-Boluda JC; Cervantes F
    Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
    Nadal E; Olavarria E
    Int J Clin Pract; 2004 May; 58(5):511-6. PubMed ID: 15206509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib: a review of its use in chronic myeloid leukaemia.
    Moen MD; McKeage K; Plosker GL; Siddiqui MA
    Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
    Zonder JA; Schiffer CA
    Curr Hematol Malig Rep; 2006 Sep; 1(3):141-51. PubMed ID: 20425345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
    Kantarjian HM; Talpaz M
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STI571 as a targeted therapy for CML.
    O'Dwyer ME; Mauro MJ; Druker BJ
    Cancer Invest; 2003 Jun; 21(3):429-38. PubMed ID: 12901289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate, the first molecularly targeted gene suppressor.
    Pindolia VK; Zarowitz BJ
    Pharmacotherapy; 2002 Oct; 22(10):1249-65. PubMed ID: 12389876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
    Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
    Sillaber C; Mayerhofer M; Agis H; Sagaster V; Mannhalter C; Sperr WR; Geissler K; Valent P
    Wien Klin Wochenschr; 2003 Aug; 115(13-14):485-504. PubMed ID: 13677268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
    Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
    Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib: the first 3 years.
    Capdeville R; Silberman S; Dimitrijevic S
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S77-82. PubMed ID: 12528777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate.
    Waller CF
    Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STI571: targeting BCR-ABL as therapy for CML.
    Mauro MJ; Druker BJ
    Oncologist; 2001; 6(3):233-8. PubMed ID: 11423669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
    Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.